4-Aminopyridine
chemical compound
4-Aminopyridine (4-AP, fampridine,
dalfampridine) is an organic compound with the chemical formula H2NC5H4N. It is one of the three isomeric aminopyridines. It is used as a research tool in characterizing subtypes of the potassium channel. It has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptomatic improvement of walking in adults with several variations of the disease. It was undergoing Phase III clinical trials as of 2008, and the U.S. Food and Drug Administration (FDA) approved the compound on January 22, 2010. 4-AP has been used as treatment for KCNA2-related disorders with gene mutations that show a clear gain-of-function. Benefits include decreased seizures and improved ataxia, alertness, and cognition. Fampridine is also marketed as Ampyra (pronounced "am-PEER-ah", according to the maker's website) in the United States by Acorda Therapeutics and as Fampyra in the European Union, Canada, and Australia. In Canada, the medication has been approved for use by Health Canada since February 10, 2012.
Applications
In the laboratory, 4-AP is a useful pharmacological tool in studying various potassium conductances in physiology and biophysics. It is a relatively selective blocker of members of Kv1 (Shaker, KCNA) family of voltage-activated K+ channels.
“4-Aminopyridine” enters the record as chemical compound. Crown Archives preserves that source wording while asking what 4-Aminopyridine, chemical and compound can confirm, complicate or overturn.
Why this record matters
“4-Aminopyridine” is worth following because a concise public description often conceals a longer documentary argument. Here, 4-Aminopyridine, chemical and compound provides the most credible route into that argument.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Jul 23, 2026. The linked authority identifier is Q372539. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2008, 2010 and 2012.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “4-Aminopyridine”, its source revision and the description used here.
- Expand the search: follow 4-Aminopyridine primary sources, 4-Aminopyridine archive and 4-Aminopyridine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “4-Aminopyridine”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “4-Aminopyridine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.